MedTrace Logo

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

NCT00426998 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-01-26

No results posted yet for this study

Summary

The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).

Conditions

  • Choroidal Neovascularization
  • Macular Degeneration

Interventions

DRUG

Verteporfin

DRUG

Bevacizumab

Sponsors & Collaborators

  • Retinal Consultants Medical Group

    lead OTHER

Principal Investigators

  • Joel A Pearlman, M.D., Ph. D. · Retinal Consultants Medical Group, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00426998 on ClinicalTrials.gov